2022
Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 670-679. PMID: 35614009, DOI: 10.1016/j.clml.2022.04.016.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeHMA therapyPoor performance statusRate of hospitalizationSEER-Medicare databaseMyelodysplastic syndromeER visitsEarly discontinuationPerformance statusEmergency roomOlder agePredictors of discontinuationEmergency room visitsHigh-risk groupHigh economic burdenTreatment discontinuationExcess blastsMore hospitalizationsNew hospitalizationRefractory anemiaRoom visitsHigh riskDiscontinuationMD diagnosisAgent use
2021
P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE. Leukemia Research 2021, 108: 106681.10. DOI: 10.1016/j.leukres.2021.106681.10.Peer-Reviewed Original Research